Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia

NCT04371367 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT04371367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04371367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2020
Completion date
March 30, 2021
Enrollment
208 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid